Stock FPLB FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fisher & Paykel Healthcare Corporation Limited Deutsche Boerse AG

Equities

FPLB

NZFAPE0001S2

Delayed Deutsche Boerse AG
Other stock markets
 11:40:22 04/06/2024 am IST 		5-day change 1st Jan Change
16.7 EUR +2.45% Intraday chart for Fisher & Paykel Healthcare Corporation Limited +5.84% +23.48%
29/05 Fisher & Paykel Healthcare Corporation Limited Provides Earnings Guidance for the Year 2025 CI
29/05 Fisher & Paykel Healthcare Corporation Limited Announces Final Dividend for the Full Year 2024, Payable on 10 July 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • With an expected P/E ratio at 50.57 and 42.07 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED Stock Fisher & Paykel Healthcare Corporation Limited
+23.48% 1.06TCr -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.54% 18TCr
C+
MEDTRONIC PLC Stock Medtronic plc
-0.32% 11TCr
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-2.05% 6.9TCr
A
DEXCOM, INC. Stock DexCom, Inc.
-7.14% 4.58TCr
B-
CENCORA, INC. Stock Cencora, Inc.
+12.24% 4.54TCr
B-
HOYA CORPORATION Stock Hoya Corporation
+8.60% 4.32TCr
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.37% 2.99TCr
B
TERUMO CORPORATION Stock Terumo Corporation
+13.65% 2.55TCr
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.64% 2.39TCr
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FPH Stock
  4. FPLB Stock
  5. Ratings Fisher & Paykel Healthcare Corporation Limited